Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease
Public ClinicalTrials.gov record NCT00428090. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 24-week, Double-blind, Double-dummy, Randomized, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets), Donepezil, and Placebo as Monotherapy on Cognition and Overall Clinical Response in APOE ε4-stratified Subjects With Mild to Moderate Alzheimer's Disease. (REFLECT-1)
Study identification
- NCT ID
- NCT00428090
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- GlaxoSmithKline
- Industry
- Enrollment
- 862 participants
Conditions and interventions
Conditions
Interventions
- Rosiglitazone Drug
Drug
Eligibility (public fields only)
- Age range
- 50 Years to 90 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 26, 2007
- Primary completion
- Aug 31, 2008
- Completion
- Sep 4, 2008
- Last update posted
- May 18, 2017
2007 – 2008
United States locations
- U.S. sites
- 41
- U.S. states
- 16
- U.S. cities
- 37
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Phoenix | Arizona | 85004 | — |
| GSK Investigational Site | Los Angeles | California | 90036 | — |
| GSK Investigational Site | Newport Beach | California | 92660 | — |
| GSK Investigational Site | Palo Alto | California | 94305 | — |
| GSK Investigational Site | Reseda | California | 91355 | — |
| GSK Investigational Site | San Diego | California | 92120 | — |
| GSK Investigational Site | San Francisco | California | 94109 | — |
| GSK Investigational Site | Denver | Colorado | 80218 | — |
| GSK Investigational Site | Fairfield | Connecticut | 06824 | — |
| GSK Investigational Site | Norwalk | Connecticut | 06851 | — |
| GSK Investigational Site | Deerfield Beach | Florida | 33064 | — |
| GSK Investigational Site | Delray Beach | Florida | 33445 | — |
| GSK Investigational Site | Destin | Florida | 32541 | — |
| GSK Investigational Site | Hialeah | Florida | 33016 | — |
| GSK Investigational Site | Melbourne | Florida | 32901 | — |
| GSK Investigational Site | Plantation | Florida | 33317 | — |
| GSK Investigational Site | Sunrise | Florida | 33351 | — |
| GSK Investigational Site | Tampa | Florida | 33647 | — |
| GSK Investigational Site | Atlanta | Georgia | 30033 | — |
| GSK Investigational Site | Saint Paul | Minnesota | 55101 | — |
| GSK Investigational Site | Las Vegas | Nevada | 89146 | — |
| GSK Investigational Site | Kenilworth | New Jersey | 07033 | — |
| GSK Investigational Site | Toms River | New Jersey | 08755 | — |
| GSK Investigational Site | Albany | New York | 12208 | — |
| GSK Investigational Site | Syracuse | New York | 13210 | — |
| GSK Investigational Site | Centerville | Ohio | 45459 | — |
| GSK Investigational Site | Cleveland | Ohio | 44120 | — |
| GSK Investigational Site | Cleveland | Ohio | 44195 | — |
| GSK Investigational Site | Toledo | Ohio | 43623 | — |
| GSK Investigational Site | Oklahoma City | Oklahoma | 73112 | — |
| GSK Investigational Site | Oklahoma City | Oklahoma | 73118 | — |
| GSK Investigational Site | Tulsa | Oklahoma | 74104 | — |
| GSK Investigational Site | Jenkintown | Pennsylvania | 19046 | — |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19102 | — |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19104 | — |
| GSK Investigational Site | Memphis | Tennessee | 35105 | — |
| GSK Investigational Site | Nashville | Tennessee | 37212 | — |
| GSK Investigational Site | DeSoto | Texas | 75115 | — |
| GSK Investigational Site | San Antonio | Texas | 78229-3900 | — |
| GSK Investigational Site | San Antonio | Texas | 78229 | — |
| GSK Investigational Site | Middleton | Wisconsin | 53562-2215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 97 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00428090, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 18, 2017 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00428090 live on ClinicalTrials.gov.